HSBC Holdings
BCAB icon

HSBC Holdings’s BioAtla BCAB Stock Holding History

HSBC Holdings’s Portfolio BCAB Stock Details BCAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-365
Closed -$54K – 2935
2022
Q2 		$54K Buy
365
+128
+54% +$20.4K ﹤0.01% 3126
2022
Q1 		$59K Buy
+237
New +$99.1K ﹤0.01% 3187

Other funds holding BCAB

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

HSBC Holdings's BCAB Position: Q3 2022 in Review

HSBC Holdings sold out of BioAtla (BCAB) in Q3 2022, closing a stake of 365 shares — an estimated $54K sold.

HSBC Holdings first reported a position in BCAB in Q1 2022 and held it in 2 quarters. The position peaked at $59K in Q1 2022. 73 funds tracked by Wall St. Rank hold BCAB as of Q3 2022.

  • HSBC Holdings reported no remaining BioAtla position as of Q3 2022 after selling out during the quarter.
  • HSBC Holdings sold 365 BioAtla shares in Q3 2022, an estimated $54K.
  • HSBC Holdings first reported a position in BioAtla in Q1 2022 and held it in 2 quarters.
  • HSBC Holdings's BioAtla position peaked at $59K in Q1 2022.
  • 73 funds tracked by Wall St. Rank held BioAtla as of Q3 2022.

Based on HSBC Holdings's 13F filing for Q3 2022, filed 14 Nov 2022.